Marksans Pharma informs about disclosure
Marksans Pharma has informed that the final approval of the Company’s wholly owned subsidiary Marksans Pharma Inc.’s Abbreviated New Drug Application (ANDA) for Omeprazole Delayed-Release Tablets, 20 mg (OTC). This product is bioequivalent to the reference listed drug (RLD), Prilosec Delayed-Release Tablets, 20 mg (OTC), of AstraZeneca Pharmaceuticals LP, NDA - 021229. Omeprazole is used to treat heartburn and certain other conditions caused by too much acid in the stomach.
The above information is a part of company’s filings submitted to BSE.
